We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


New Kanamycin and Amikacin Method Exceeds US Pharmacopeia Analysis Requirements

Want a FREE PDF version of this product news?

Complete the form below and we will email you a PDF version of "New Kanamycin and Amikacin Method Exceeds US Pharmacopeia Analysis Requirements"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Application Note 267: Analysis of the Aminoglycoside Antibiotics Kanamycin and Amikacin Matches USP Requirements demonstrates peak resolution between kanamycin and amikacin is >4, exceeding the United States Pharmacopeia (USP) requirement of 3. The asymmetry for both kanamycin and amikacin is 1.1 (USP requires <2). The total analysis time is 10 min, providing high sample throughput.

Kanamycin and amikacin are broad-spectrum aminoglycoside antibiotics that are used to treat a wide variety of serious gramnegative- bacterial infections. The USP monographs for kanamycin and amikacin (and drug products made from either of the two) use anion-exchange assays with pulsed amperometric detection according to USP L47. The new Dionex method uses the CarboPac® MA1 column with hydroxide eluent, a disposable gold (Au) working electrode, and a 4-potential waveform. The disposable gold working electrode provides consistently high detector response, assuring greater instrument-to-instrument and lab-to-lab reproducibility. The waveform allows monitoring of the forced acid or base degradation of both drug substances. The method is shown to be accurate and reliable and meets the USP requirements for peak resolution, tailing (asymmetry), and reproducibility.